Rgenix is a preclinical stage pharmaceutical company with a mission to develop the world's first cancer therapies designed specifically to target cancer metastasis, the main cause of mortality in cancer patients. Rgenix is leading the revolution in next-generation cancer therapies with first-in-class lead drug candidates for several aggressive cancer subtypes, including Melanoma, Colorectal Cancer, and Triple-Negative Breast Cancer.
Sohail Tavazoie and Saeed Tavazoie publish new findings on breast cancer metastasis, in Nature
Tavazoie Lab publishes on a novel mechanism to combat melanoma, in Cell
Tavazoie Lab publishes on a miRNA network underlying melanoma metastasis, in Cell
In cancer, molecular signals that recruit blood vessels also trigger metastasis